Skip to main content
Top
Published in: International Journal of Hematology 4/2016

01-10-2016 | Original Article

Serum ferritin is an independent factor in coronary artery stenosis among hemodialysis patients

Authors: Chen-Tung Lien, Chiang-Chin Tsai, Chien-An Chen, Chieh Kuo, Meng-Yi Tsai

Published in: International Journal of Hematology | Issue 4/2016

Login to get access

Abstract

Hemodialysis patients frequently receive intravenous iron for the treatment of anemia. Iron status has been found to be correlated with coronary artery disease. In the post hoc study reported here, we evaluate the association between iron status and coronary arterial stenosis (CAS) in a 3-year follow-up period. We enrolled 76 patients and collected iron status, and clinical/biochemical data over 3 years. In this study, coronary arterial stenosis was considered significant when the narrowing of the coronary artery exceeded 50 % of the luminal diameter on coronary angiography. The mean age was 61 years old. The female/male ratio was 48/28, and the group included 16 diabetic patients and 23 smokers. Twenty-two of 76 patients had CAS. Mean intravenous iron dosage was 2167.11 ± 1738.38 in a 3-year period. On the univariate regression analysis, 3-year-averaged serum ferritin was positively associated with CAS (r = 0.288, P = 0.012). The 3-year-averaged intravenous iron dosage, DM, age, smoking, and other biochemical parameters showed no association with CAS. When these factors were added to the multivariate-adjusted models, 3-year-averaged serum ferritin remained a determinant of CAS event (β = 0.290, P = 0.029). The odds ratio for CAS was 6.93 (95 % CI 2.41–19.94; P = 0.001) for patients with 3-year-averaged serum ferritin ≥600 ng/mL. In summary, serum ferritin was an independent risk factor for CAS among this group of hemodialysis patients, especially when serum ferritin was ≥600 ng/mL.
Literature
1.
go back to reference Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–23.PubMed Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998;9(12 Suppl):S16–23.PubMed
2.
go back to reference Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.CrossRefPubMed Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.CrossRefPubMed
3.
go back to reference Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–81.CrossRefPubMed Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992;268:877–81.CrossRefPubMed
4.
go back to reference Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case–control study in a general population sample of middle aged men. BMJ. 1990;301:1248–51.CrossRefPubMedPubMedCentral Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: a prospective case–control study in a general population sample of middle aged men. BMJ. 1990;301:1248–51.CrossRefPubMedPubMedCentral
5.
go back to reference Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277–85.CrossRefPubMed Parfrey PS, Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant. 1996;11:1277–85.CrossRefPubMed
6.
go back to reference Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529–38.CrossRefPubMed Muntner P, He J, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529–38.CrossRefPubMed
7.
go back to reference Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–38.CrossRefPubMed Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524–38.CrossRefPubMed
8.
go back to reference Ramakrishna G, Rooke TW, Cooper LT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med. 2003;8:203–10.CrossRefPubMed Ramakrishna G, Rooke TW, Cooper LT. Iron and peripheral arterial disease: revisiting the iron hypothesis in a different light. Vasc Med. 2003;8:203–10.CrossRefPubMed
9.
go back to reference Vinchi F, Muckenthaler MU, Da Silva MC, Balla G, Balla J, Jeney V. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol. 2014;5:94.CrossRefPubMedPubMedCentral Vinchi F, Muckenthaler MU, Da Silva MC, Balla G, Balla J, Jeney V. Atherogenesis and iron: from epidemiology to cellular level. Front Pharmacol. 2014;5:94.CrossRefPubMedPubMedCentral
10.
11.
go back to reference Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212–7.CrossRefPubMed Drueke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212–7.CrossRefPubMed
12.
go back to reference Lien CT, Lin KC, Tsai YF, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with progression of peripheral arterial disease in hemodialysis patients. Clin Exp Nephrol. 2015;19:947–52.CrossRefPubMed Lien CT, Lin KC, Tsai YF, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with progression of peripheral arterial disease in hemodialysis patients. Clin Exp Nephrol. 2015;19:947–52.CrossRefPubMed
13.
go back to reference Lin KC, Tsai MY, Chi CL, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with arterial stiffness in hemodialysis patients: results of a 3-year follow-up study. Int Urol Nephrol. 2015;47:1847–53.CrossRefPubMed Lin KC, Tsai MY, Chi CL, Yu LK, Huang LH, Chen CA. Serum ferritin is associated with arterial stiffness in hemodialysis patients: results of a 3-year follow-up study. Int Urol Nephrol. 2015;47:1847–53.CrossRefPubMed
14.
go back to reference Le Feuvre C, Dambrin G, Helft G, Beygui F, Touam M, Grunfeld JP, et al. Clinical outcome following coronary angioplasty in dialysis patients: a case–control study in the era of coronary stenting. Heart. 2001;85:556–60.CrossRefPubMedPubMedCentral Le Feuvre C, Dambrin G, Helft G, Beygui F, Touam M, Grunfeld JP, et al. Clinical outcome following coronary angioplasty in dialysis patients: a case–control study in the era of coronary stenting. Heart. 2001;85:556–60.CrossRefPubMedPubMedCentral
15.
go back to reference Yasuda K, Kasuga H, Aoyama T, Takahashi H, Toriyama T, Kawade Y, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 2006;17:2322–32.CrossRefPubMed Yasuda K, Kasuga H, Aoyama T, Takahashi H, Toriyama T, Kawade Y, et al. Comparison of percutaneous coronary intervention with medication in the treatment of coronary artery disease in hemodialysis patients. J Am Soc Nephrol. 2006;17:2322–32.CrossRefPubMed
16.
go back to reference Senol E, Ersoy A, Erdinc S, Sarandol E, Yurtkuran M. Oxidative stress and ferritin levels in haemodialysis patients. Nephrol Dial Transplant. 2008;23:665–72.CrossRefPubMed Senol E, Ersoy A, Erdinc S, Sarandol E, Yurtkuran M. Oxidative stress and ferritin levels in haemodialysis patients. Nephrol Dial Transplant. 2008;23:665–72.CrossRefPubMed
17.
go back to reference KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47:S11–145. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47:S11–145.
18.
go back to reference Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005;16:1141–8.CrossRefPubMed Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005;16:1141–8.CrossRefPubMed
19.
go back to reference Bal Z, Bal U, Okyay K, Yilmaz M, Balcioglu S, Turgay O, et al. Hematological parameters can predict the extent of coronary artery disease in patients with end-stage renal disease. Int Urol Nephrol. 2015;47:1719–25.CrossRefPubMed Bal Z, Bal U, Okyay K, Yilmaz M, Balcioglu S, Turgay O, et al. Hematological parameters can predict the extent of coronary artery disease in patients with end-stage renal disease. Int Urol Nephrol. 2015;47:1719–25.CrossRefPubMed
20.
go back to reference Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864–81.CrossRefPubMed Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition–inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003;42:864–81.CrossRefPubMed
21.
go back to reference Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803–11.CrossRefPubMed Salonen JT, Nyyssonen K, Korpela H, Tuomilehto J, Seppanen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation. 1992;86(3):803–11.CrossRefPubMed
22.
go back to reference Haidari M, Javadi E, Sanati A, Hajilooi M, Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem. 2001;47:1666–72.PubMed Haidari M, Javadi E, Sanati A, Hajilooi M, Ghanbili J. Association of increased ferritin with premature coronary stenosis in men. Clin Chem. 2001;47:1666–72.PubMed
23.
go back to reference Klipstein-Grobusch K, Koster JF, Grobbee DE, Lindemans J, Boeing H, Hofman A, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69:1231–6.PubMed Klipstein-Grobusch K, Koster JF, Grobbee DE, Lindemans J, Boeing H, Hofman A, et al. Serum ferritin and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69:1231–6.PubMed
24.
go back to reference van der A DL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-Renaud JH, et al. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation. 2006;113:1942–9.CrossRef van der A DL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-Renaud JH, et al. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation. 2006;113:1942–9.CrossRef
25.
go back to reference Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB. Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr. 2008;138:2436–41.CrossRefPubMedPubMedCentral Sun Q, Ma J, Rifai N, Franco OH, Rexrode KM, Hu FB. Excessive body iron stores are not associated with risk of coronary heart disease in women. J Nutr. 2008;138:2436–41.CrossRefPubMedPubMedCentral
26.
go back to reference Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol. 2003;158:144–9.CrossRefPubMed Knuiman MW, Divitini ML, Olynyk JK, Cullen DJ, Bartholomew HC. Serum ferritin and cardiovascular disease: a 17-year follow-up study in Busselton, Western Australia. Am J Epidemiol. 2003;158:144–9.CrossRefPubMed
27.
go back to reference Sempos CT, Looker AC, Gillum RE, McGee DL, Vuong CV, Johnson CL. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol. 2000;10:441–8.CrossRefPubMed Sempos CT, Looker AC, Gillum RE, McGee DL, Vuong CV, Johnson CL. Serum ferritin and death from all causes and cardiovascular disease: the NHANES II Mortality Study. National Health and Nutrition Examination Study. Ann Epidemiol. 2000;10:441–8.CrossRefPubMed
28.
go back to reference Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. Arterioscler Thromb Vasc Biol. 2012;32:2525–30.CrossRefPubMed Sung KC, Kang SM, Cho EJ, Park JB, Wild SH, Byrne CD. Ferritin is independently associated with the presence of coronary artery calcium in 12,033 men. Arterioscler Thromb Vasc Biol. 2012;32:2525–30.CrossRefPubMed
29.
go back to reference Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S, et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107:2601–6.PubMed Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S, et al. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003;107:2601–6.PubMed
30.
go back to reference Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood). 2010;235:633–41.CrossRef Zhang WJ, Wei H, Frei B. The iron chelator, desferrioxamine, reduces inflammation and atherosclerotic lesion development in experimental mice. Exp Biol Med (Maywood). 2010;235:633–41.CrossRef
31.
go back to reference Rocha LA, Barreto DV, Barreto FC, Dias CB, Moyses R, Silva MR, et al. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:105–9.CrossRefPubMedPubMedCentral Rocha LA, Barreto DV, Barreto FC, Dias CB, Moyses R, Silva MR, et al. Serum ferritin level remains a reliable marker of bone marrow iron stores evaluated by histomorphometry in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:105–9.CrossRefPubMedPubMedCentral
32.
go back to reference Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl 2):25–9.CrossRefPubMed Kletzmayr J, Horl WH. Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant. 2002;17(Suppl 2):25–9.CrossRefPubMed
33.
go back to reference Ellervik C, Marott JL, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific mortality by moderately and markedly increased ferritin concentrations: general population study and metaanalysis. Clin Chem. 2014;60:1419–28.CrossRefPubMed Ellervik C, Marott JL, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Total and cause-specific mortality by moderately and markedly increased ferritin concentrations: general population study and metaanalysis. Clin Chem. 2014;60:1419–28.CrossRefPubMed
34.
go back to reference Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br Med J. 1972;4:206–8.CrossRefPubMedPubMedCentral Jacobs A, Miller F, Worwood M, Beamish MR, Wardrop CA. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. Br Med J. 1972;4:206–8.CrossRefPubMedPubMedCentral
35.
go back to reference Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1(Suppl):S9–18.CrossRefPubMed Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1(Suppl):S9–18.CrossRefPubMed
36.
go back to reference Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691–701.CrossRefPubMedPubMedCentral Rambod M, Kovesdy CP, Kalantar-Zadeh K. Combined high serum ferritin and low iron saturation in hemodialysis patients: the role of inflammation. Clin J Am Soc Nephrol. 2008;3:1691–701.CrossRefPubMedPubMedCentral
37.
go back to reference Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141–9.CrossRefPubMed Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant. 2004;19(1):141–9.CrossRefPubMed
Metadata
Title
Serum ferritin is an independent factor in coronary artery stenosis among hemodialysis patients
Authors
Chen-Tung Lien
Chiang-Chin Tsai
Chien-An Chen
Chieh Kuo
Meng-Yi Tsai
Publication date
01-10-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2045-8

Other articles of this Issue 4/2016

International Journal of Hematology 4/2016 Go to the issue

Images in Hematology

Atypical amyloid deposits

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine